×
Again, a PARP Inhibitor Has Potential in BRCA+ Breast Cancer
http://www.medscape.com/viewarticle/889875

Dec 11th, 2017 - A second PARP inhibitor shows promise in germline mutation metastatic breast cancer and is generally well tolerated compared with standard chemotherapy.

Adjuvant Zoledronic Acid in Early Breast Cancer: Is 5 Years Better?
http://www.ascopost.com/issues/february-10-2018/adjuvant-zoledronic-acid-in-early-breast-cancer-is-5-years-better/

Feb 10th, 2018 - THE PHASE III SUCCESS A trial, presented at the 2017 San Antonio Breast Cancer Symposium, found no benefit for extending the use of intravenous zoledronic acid from 2 years to 5 years.

Axillary Node Management for Breast Cancer: Is Less More?
https://www.cancertherapyadvisor.com/breast-cancer/breast-cancer-axillary-node-management-treatment/article/713742/

Dec 12th, 2017 - Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings.

Breast Pain Uncommon Symptom of Breast Cancer
http://www.medscape.com/viewarticle/890247

Dec 18th, 2017 - Breast pain is not often a symptom of breast cancer regardless of age, and mostly women need to be reassured that breast pain is both common and benign.

CDK 4/6 Inhibitors May Be Effective but More Toxic in Older Women
http://www.ascopost.com/issues/february-10-2018/cdk-46-inhibitors-may-be-effective-but-more-toxic-in-older-women/

Feb 10th, 2018 - OLDER WOMEN with breast cancer derive benefit from treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors as part of initial endocrine-based therapy for hormone receptor–positive, HER2-negative, metastatic breast cancer, according to a retrospective pooled subgroup analysis of women aged 70 or older enrolled in registration trials of these agents.

CDK4/6 Improved PFS in Older Women with HR+ Metastatic Breast Cancer
https://www.onclive.com/conference-coverage/sabcs-2017/cdk46-improved-pfs-in-older-women-with-hr-metastatic-breast-cancer-

Dec 8th, 2017 - Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival  benefit similar to that seen in their younger counterparts

Dosing Modifications Shown to Improve Outcomes In Breast Cancer
https://www.targetedonc.com/conference/2017-sabcs/dosing-modifications-shown-to-improve-outcomes-in-breast-cancer

Dec 6th, 2017 - Early-stage breast cancer recurrence and mortality was reduced by shortening the intervals between chemotherapy cycles or administering the drugs sequentially compared with standard dosing techniques, according to meta-analysis results presented at the 2017 San Antonio Breast Cancer Symposium.

Enzalutamide plus exemestane improves PFS in HR+ breast cancer subset
https://www.mdedge.com/oncologypractice/article/155272/breast-cancer/enzalutamide-plus-exemestane-improves-pfs-hr-breast

Jan 2nd, 2018 - Enzalutamide added to exemestane improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive advanced breast cancer, investigators reported

ERBB2 expression predicts pCR in HER2+ breast cancer
https://www.mdedge.com/oncologypractice/article/155137/breast-cancer/erbb2-expression-predicts-pcr-her2-breast-cancer

Dec 26th, 2017 - Among patients receiving trastuzumab plus lapatinib neoadjuvant therapy for HER2-positive early breast cancer, amplification of ERBB2 was predictive of a pathologic complete response (pCR), according to findings presented at the San Antonio Breast Cancer Symposium.

Exemestane plus enzalutamide extends PFS in some women with breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B99e9af8c-7703-431e-ab0d-71b296bb9b5b%7D/exemestane-plus-enzalutamide-extends-pfs-in-some-women-with-breast-cancer

Dec 8th, 2017 - The addition of enzalutamide to exemestane significantly prolonged PFS and appeared well tolerated among patients with hormone receptor-positive metastatic breast cancer who had not received prior endocrine therapy and who expressed an androgen receptor gene signature, according to results of a placebo-controlled randomized phase 2 trial presented at the San Antonio Breast Cancer Symposium.

Extended Endocrine Therapy in Postmenopausal Women With Breast Cancer: 2 Years as Effective as 5 Years
http://www.ascopost.com/issues/december-25-2017/extended-endocrine-therapy-in-postmenopausal-women-with-breast-cancer-2-years-as-effective-as-5-years/

Dec 25th, 2017 - An additional 5 years of aromatase inhibitor therapy after 5 years of adjuvant endocrine therapy failed to improve disease-free survival compared with an additional 2 years of aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive breast cancer, according to the results of the large Austrian Breast and Colorectal Cancer Study Group (ABCSG)-16 trial presented at the 2...

Fulvestrant + Anastrozole Improves Long-Term PFS and OS vs Anastrozole Alone in Women With Postmenopausal Metastatic Breast Cancer
https://www.practiceupdate.com/content/sabcs-2017nbspfulvestrant-anastrozole-improves-long-term-pfs-and-os-vs-anastrozole-alone-in-women-with-postmenopausal-metastatic-breast-cancer/61146/62

Dec 8th, 2017 - Fulvestrant + anastrozole has been shown to improve long-term progression-free and overall survival vs anastrozole alone in women with postmenopausal metastatic breast cancer, despite the use of fulvestrant at a lower dose than approved, and despite substantial crossover to fulvestrant after progression with anastrozole alone.

Gene-Based Biomarker Identifies Patients With Breast Cancer More Likely to Respond to Enzalutamide
https://www.onclive.com/conference-coverage/sabcs-2017/genebased-biomarker-identifies-patients-with-breast-cancer-more-likely-to-respond-to-enzalutamide

Dec 8th, 2017 - Enzalutamide (Xtandi) added to exemestane improved progression-free survival in patients with hormone receptor-positive advanced breast cancer and no prior endocrine therapy who were positive for a gene signature-based biomarker indicating androgen receptor-signaling.

Lapatinib plus trastuzumab improves outcomes in HER2+ breast cancer
https://www.mdedge.com/oncologypractice/article/155150/breast-cancer/lapatinib-plus-trastuzumab-improves-outcomes-her2

Dec 27th, 2017 - Results from CALGB 40601 conflict with those from two larger trials that failed to find a benefit for dual HER2 blockade in treating HER2+ breast cancer.

High rate of arm morbidity in young breast cancer survivors
https://www.mdedge.com/oncologypractice/article/154705/breast-cancer/high-rate-arm-morbidity-young-breast-cancer-survivors

Dec 18th, 2017 - Undergoing axillary lymph node dissection (ALND) is more likely to result in arm swelling and decreased range of arm motion in young breast cancer patients, as compared with having a sentinel lymph node biopsy (SLNB), according to new findings.

Modest Weight Loss Cuts Postmenopausal Breast Cancer Risk
http://www.medscape.com/viewarticle/889854

Dec 11th, 2017 - Women who lose just 5% of their body weight after the menopause may experience a significant reduction in their risk of developing breast cancer vs women with stable weight, say US researchers.

Poor Prognostic Markers Predict for Abemaciclib Benefit in Patients With Breast Cancer
https://www.cancertherapyadvisor.com/breast-cancer/abemaciclib-benefit-breast-cancer-poor-prognostic-markers-risk/article/713426/

Dec 11th, 2017 - This analysis was undertaken to determine whether patient and disease characteristics can predict which patients will benefit from abemaciclib.

Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer
https://ecancer.org/conference/966-sabcs-2017/news/12915-sabcs-2017--phase-iii-trial-data-supports-current-standard-12-month-adjuvant-trastuzumab-for-her2-positive-breast-cancer.php

Dec 7th, 2017 - Disease-free survival (DFS) after nine weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to DFS after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment, according to data from the phase III Synergism or Long Duration (SOLD) clinical trial, ...

Ribociclib Doubles Progression-Free Survival in Premenopausal Breast Cancer
http://www.ascopost.com/issues/december-25-2017/ribociclib-doubles-progression-free-survival-in-premenopausal-breast-cancer/

Dec 25th, 2017 - PREMENOPAUSAL WOMEN with hormone receptor–positive, HER2-negative advanced breast cancer benefited substantially from the addition of ribociclib (Kisqali) to first-line endocrine therapy plus medical ovarian suppression, according to results from the MONALEESA-7 study.

Researchers quantify presence of immunotherapy biomarkers in breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B4ee9505a-d5b1-4da3-b899-d6c77ebc5a22%7D/researchers-quantify-presence-of-immunotherapy-biomarkers-in-breast-cancer

Dec 8th, 2017 - Although a minority of patients with invasive breast cancer expressed microsatellite instability, high tumor mutational load or PD-L1 expression, these biomarkers may elucidate the benefit of immune checkpoint inhibitors for the disease, according to results of a retrospective data analysis presented at the San Antonio Breast Cancer Symposium.